426 related articles for article (PubMed ID: 24516026)
1. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
[TBL] [Abstract][Full Text] [Related]
2. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
Burke PW; Aldoss I; Lunning MA; Devlin SM; Tallman MS; Pullarkat V; Mohrbacher AM; Douer D
Leuk Res; 2018 Mar; 66():49-56. PubMed ID: 29407583
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.
Douer D; Yampolsky H; Cohen LJ; Watkins K; Levine AM; Periclou AP; Avramis VI
Blood; 2007 Apr; 109(7):2744-50. PubMed ID: 17132721
[TBL] [Abstract][Full Text] [Related]
4. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
5. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Vrooman LM; Blonquist TM; Stevenson KE; Supko JG; Hunt SK; Cronholm SM; Koch V; Kay-Green S; Athale UH; Clavell LA; Cole PD; Harris MH; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Place AE; Schorin MA; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2021 Nov; 39(31):3496-3505. PubMed ID: 34228505
[TBL] [Abstract][Full Text] [Related]
7. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
8. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Geyer MB; Ritchie EK; Rao AV; Vemuri S; Flynn J; Hsu M; Devlin SM; Roshal M; Gao Q; Shukla M; Salcedo JM; Maslak P; Tallman MS; Douer D; Park JH
Haematologica; 2021 Aug; 106(8):2086-2094. PubMed ID: 33054114
[TBL] [Abstract][Full Text] [Related]
9. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
[TBL] [Abstract][Full Text] [Related]
11. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Heo YA; Syed YY; Keam SJ
Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV
Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389
[TBL] [Abstract][Full Text] [Related]
14. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
Daley RJ; Rajeeve S; Kabel CC; Pappacena JJ; Stump SE; Lavery JA; Tallman MS; Geyer MB; Park JH
Leuk Lymphoma; 2021 Jan; 62(1):176-184. PubMed ID: 32985296
[TBL] [Abstract][Full Text] [Related]
16. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
17. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
18. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
19. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Larson RA; Fretzin MH; Dodge RK; Schiffer CA
Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
[TBL] [Abstract][Full Text] [Related]
20. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Salzer WL; Asselin B; Supko JG; Devidas M; Kaiser NA; Plourde P; Winick NJ; Reaman GH; Raetz E; Carroll WL; Hunger SP
Blood; 2013 Jul; 122(4):507-14. PubMed ID: 23741010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
